Savvy Advisors Inc. Has $223,000 Position in Zoetis Inc. (NYSE:ZTS)

Savvy Advisors Inc. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 15.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,369 shares of the company’s stock after acquiring an additional 185 shares during the period. Savvy Advisors Inc.’s holdings in Zoetis were worth $223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Callahan Advisors LLC boosted its holdings in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Pensionfund Sabic boosted its holdings in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the last quarter. PFW Advisors LLC bought a new stake in Zoetis in the 4th quarter worth about $1,764,000. Finally, Schroder Investment Management Group increased its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after buying an additional 6,169 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 1.1 %

ZTS stock opened at $149.15 on Wednesday. The stock has a 50-day simple moving average of $161.51 and a two-hundred day simple moving average of $170.76. The firm has a market capitalization of $66.55 billion, a PE ratio of 27.27, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.34%. Zoetis’s payout ratio is 36.56%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $214.40.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. Corporate insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.